Sorafenib, a FLT3 inhibitor, through the downregulation of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7, enhances IL-15 transcription in FLT3+ AML cells, which causes an increase in CD8+CD107a+IFN-γ+ T cells and is capable of eradicating leukemia cells [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.